**Supplementary Table 2.** The accuracy of NITs for progression or regression of MASLD.

|  |  |  |  |
| --- | --- | --- | --- |
| Changes in disease status | Name of NITs | Number of participants | AUC (95% CI) or C-statistic (95% CI) |
| **Any progression in fibrosis stage** | APRI[51] | 282 | 0.70 (0.63, 0.77) # |
| FIB-4[51] | 282 | 0.73 (0.67, 0.79) # |
| AST/ALT ratio[51] | 282 | 0.57 (0.50, 0.64) # |
| NAFLD fibrosis score[51] | 282 | 0.66 (0.59, 0.73) # |
|  |  |  |  |
| **Progression to advanced fibrosis** | APRI[51] | 216 | 0.82 (0.74, 0.89) # |
| FIB-4[51] | 216 | 0.81 (0.73, 0.89) # |
| AST/ALT ratio[51] | 216 | 0.68 (0.59, 0.77) # |
| NAFLD fibrosis score[51] | 216 | 0.80 (0.71,0.88) # |
|  |
| **Progression to cirrhosis** | LSM by VCTE[53] | 664 | 0.72 (0.66, 0.77) # |
| Agile 3+[53] | 629 | 0.70 (0.64, 0.76) # |
|  |
| **Progression to liver-related events** | Agile 3+[57] | 12 948 | 0.89 (0.85-0.92) ## |
| Agile 4[57] | 12 948 | 0.88 (0.85-0.91) ## |
| LSM[57] | 16 603 | 0.85 (0.82-0.88) ## |
| FIB-4[57] | 12 950 | 0.84 (0.81-0.88) ## |
| NFS[57] | 12 064 | 0.84 (0.80-0.88) ## |
| APRI[57] | 12 975 | 0.79 (0.75-0.83) ## |
| FAST[57] | 11 541 | 0.78 (0.74-0.83) ## |
| AAR[57] | 13 159 | 0.67 (0.62-0.71) ## |
| BARD[57] | 12 498 | 0.69 (0.65-0.73) ## |
| acFibroMASH[46] | 9034 | 0.84 (0.79-0.88) ## |
| **Progression to HCC** | Agile 3+[57] | 12 948 | 0.80 (0.73-0.87) ## |
| Agile 4[57] | 12 948 | 0.80 (0.73-0.86) ## |
| LSM[57] | 16 603 | 0.76 (0.69-0.82) ## |
| FIB-4[57] | 12 950 | 0.77 (0.71-0.83) ## |
| NFS[57] | 12 064 | 0.77 (0.70-0.83) ## |
| APRI[57] | 12 975 | 0.72 (0.65-0.78) ## |
| FAST[57] | 11 541 | 0.74 (0.67-0.81) ## |
| AAR[57] | 13 159 | 0.64 (0.57-0.70) ## |
| BARD[57] | 12 498 | 0.63 (0.56-0.69) ## |
|  |  |  |  |
|  |  |  |  |
| **Progression to hepatic decompensation** | Agile 3+[57] | 12 948 | 0.94 (0.91-0.96) ## |
| Agile 4[57] | 12 948 | 0.93 (0.90-0.96) ## |
| LSM[57] | 16 603 | 0.90 (0.88-0.94) ## |
| FIB-4[57] | 12 950 | 0.88 (0.85-0.92) ## |
| NFS[57] | 12 064 | 0.89 (0.86-0.93) ## |
| APRI[57] | 12 975 | 0.84 (0.79-0.88) ## |
| FAST[57] | 11 541 | 0.81 (0.75-0.86) ## |
| AAR[57] | 13 159 | 0.68 (0.64-0.73) ## |
| BARD[57] | 12 498 | 0.73 (0.68-0.77) ## |
|  |  |  |  |
| **Prediction of histological**  **resolution of MASH** | MASH Resolution Index[62] | Derivation cohort (n=95); validation cohort (n=163) | 0.81 (0.69-0.93) in derivation cohort; 0.83 (0.76-0.91) in validation cohort ## |
| Reduction in FAST score[64] | 93 received semaglutide | 0.69 (0.58, 0.81) ## |

*Note:* # C-statistic; ##AUROC.

*Abbreviations*: AUROC, area under the receiver operating characteristic curve; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; NITs, non-invasive tests.